Donor immune-cell treatment for stubborn CMV or adenovirus after transplant
Part of Infections clinical trials.
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a blood stem cell transplant from a haploidentical donor or a matched donor, and now you have CMV and/or adenovirus in the blood by PCR testing
- Your virus is not responding to antivirals after at least 14 days, or it is rising after 7 days
- You should NOT have signs of graft-versus-host disease (GVHD) that are suspected or confirmed
- You must have a suitable haploidentical donor available to collect cells for this immune-cell therapy
- No donor lymphocyte infusion in the last 4 weeks
- You must meet key safety checks like enough heart/kidney/liver function and no uncontrolled severe infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding specially trained immune cells (CTLs) from a related donor to standard treatment helps clear persistent adenovirus or CMV infections after a stem cell transplant. It may be an option if standard antiviral therapy isn't working or causes serious side effects.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
Hear when a new Cytomegalovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.